Clinical Study
The Routine Use of Prophylactic Oxytocin in the Third Stage of Labor to Reduce Maternal Blood Loss
Table 2
The main outcomes and other factors associated with RUPO.
| | | Control group
() | RUPO group
() | value |
| | Maternal blood loss (ml) | | | | | Median (range) (ml) | 562 (96–3,404) | 428 (68–2,860) | | | PPH ≥ 1,000 mL (%) | 57 (14.0%) | 24 (6.1%) | | | PPH ≥ 1,500 mL (%) | 13 (3.2%) | 6 (1.5%) | NS () | | Blood transfusion (%) | 3 (0.7%) | 2 (0.5%) | NS | | Rate of oxytocin use (%) | 289 (71%) | 392 (100%) | | | Dose of oxytocin (IU) | | | | | Additional uterotonic agents (%) | 27 (6.6%) | 40 (10.2%) | NS | | Duration of third stage of labor (min) | | | NS | | Manual removal of placenta (%) | 7 (1.7%) | 7 (1.8%) | NS |
|
|
RUPO, routine use of prophylactic oxytocin; PPH, postpartum hemorrhage.
|
